[go: nahoru, domu]

WO2008135829A3 - Nanoparticles comprising cox-2 inhibitors and a non-ionizable polymer - Google Patents

Nanoparticles comprising cox-2 inhibitors and a non-ionizable polymer Download PDF

Info

Publication number
WO2008135829A3
WO2008135829A3 PCT/IB2008/001061 IB2008001061W WO2008135829A3 WO 2008135829 A3 WO2008135829 A3 WO 2008135829A3 IB 2008001061 W IB2008001061 W IB 2008001061W WO 2008135829 A3 WO2008135829 A3 WO 2008135829A3
Authority
WO
WIPO (PCT)
Prior art keywords
cox
nanoparticles
inhibitors
ionizable polymer
ionizable
Prior art date
Application number
PCT/IB2008/001061
Other languages
French (fr)
Other versions
WO2008135829A2 (en
Inventor
Corey Jay Bloom
Marshall David Crew
Warren Kenyon Miller
Michael Mark Morgen
Daniel Tod Smithey
Original Assignee
Pfizer Prod Inc
Corey Jay Bloom
Marshall David Crew
Warren Kenyon Miller
Michael Mark Morgen
Daniel Tod Smithey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Corey Jay Bloom, Marshall David Crew, Warren Kenyon Miller, Michael Mark Morgen, Daniel Tod Smithey filed Critical Pfizer Prod Inc
Publication of WO2008135829A2 publication Critical patent/WO2008135829A2/en
Publication of WO2008135829A3 publication Critical patent/WO2008135829A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A pharmaceutical composition comprises nanoparticles comprising a COX-2 inhibitor and a poorly aqueous soluble non-ionizable polymer.
PCT/IB2008/001061 2007-05-03 2008-04-21 Nanoparticles comprising cox-2 inhibitors and a non-ionizable polymer WO2008135829A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91569707P 2007-05-03 2007-05-03
US60/915,697 2007-05-03

Publications (2)

Publication Number Publication Date
WO2008135829A2 WO2008135829A2 (en) 2008-11-13
WO2008135829A3 true WO2008135829A3 (en) 2009-03-12

Family

ID=39534837

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/001061 WO2008135829A2 (en) 2007-05-03 2008-04-21 Nanoparticles comprising cox-2 inhibitors and a non-ionizable polymer

Country Status (1)

Country Link
WO (1) WO2008135829A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142045A1 (en) * 1999-12-08 2002-10-03 Kararli Tugrul T. Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
WO2006062875A1 (en) * 2004-12-08 2006-06-15 Merck & Co., Inc. Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142045A1 (en) * 1999-12-08 2002-10-03 Kararli Tugrul T. Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
WO2006062875A1 (en) * 2004-12-08 2006-06-15 Merck & Co., Inc. Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MCCARRON PAUL A ET AL: "Celecoxib-loaded poly(D,L-lactide-co-glycolide) nanoparticles prepared using a novel and controllable combination of diffusion and emulsification steps as part of the salting-out procedure", JOURNAL OF MICROENCAPSULATION, TAYLOR AND FRANCIS, BASINGSTOKE, GB, vol. 23, no. 5, 1 August 2006 (2006-08-01), pages 480 - 498, XP008097270, ISSN: 0265-2048 *

Also Published As

Publication number Publication date
WO2008135829A2 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
WO2008135855A3 (en) Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
WO2009010837A3 (en) Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer
WO2008149192A3 (en) Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
EP2497470B8 (en) Imidazotriazines and imidazopyrimidines as kinase inhibitors
WO2009010842A3 (en) Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
WO2009142731A3 (en) Niacin and nsaid for combination therapy
EP1998751A4 (en) Devices, systems and methods for medicament delivery
PL2087028T3 (en) Water-soluble film
WO2007148300A3 (en) Methods and systems for push-to-storage
IL204442A (en) F1f0-atpase inhibitors, pharmaceutical compositions comprising them and use thereof
BRPI0917358A2 (en) controlled release pharmaceutical formulation and method.
EP2198003A4 (en) Microfluidic platforms for multi-target detection
WO2008016602A3 (en) Free base gacyclidine nanoparticles
WO2009151920A9 (en) Hepsin inhibitors
EP2144663A4 (en) Systems and methods for delivering a fluid drug
HK1131157A1 (en) Estratriene derivatives and their uses as 17beta-hydroxysteroid dehydrogenase inhibitors
EP2240162A4 (en) Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
WO2007131689A3 (en) Pharmaceutical combinations comprising a mtor inhibitor and a raf kinase inhibitor
AU2007337830A8 (en) Benzenesulfonamide derivatives as HIV protease inhibitors
WO2008135828A3 (en) Nanoparticles comprising a drug, ethylcellulose, and a bile salt
EP2191431A4 (en) Methods and systems for trading options and other derivatives
BRPI0923586A2 (en) pressure pipes and polyolefin composition for their manufacture.
WO2008156645A3 (en) Pharmaceutical compositions and uses
WO2008149230A3 (en) Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
WO2008029414A3 (en) Use of transcription factor inhibitor in the manufacture of a medicament

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08737567

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08737567

Country of ref document: EP

Kind code of ref document: A2